Biology, life sciences
Biomarker Tests for Molecularly Targeted Therapies
Key to Unlocking Precision Medicine
by Laurene A. Graig, Jonathan K. Phillips, and Harold L. Moses, Editors; Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine
Description
Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time. In an era of rapid advances in biomedicine and enhanced understanding of the genetic basis of disease, health care providers increasingly have access to advanced technologies that may identify molecular variations specific to an individual patient, which subsequently can be targeted for treatment. Known as biomarker tests for molecularly targeted therapies, these complex tests have the potential to enable the selection of the most beneficial treatment (and also to identify treatments that may be harmful or ineffective) for the molecular underpinnings of an individual patient’s disease. Such tests are key to unlocking the promise of precision medicine.
Biomarker tests for molecularly targeted therapies represent a crucial area of focus for developing methods that could later be applicable to other areas of precision medicine. The appropriate regulatory oversight of these tests is required to ensure that they are accurate, reliable, properly validated, and appropriately implemented in clinical practice. Moreover, common evidentiary standards for assessing the beneficial impact of biomarker-guided therapy selection on patient outcomes, as well as the effective collection and sharing of information related to those outcomes, are urgently needed to better inform clinical decision making.
Biomarker Tests of Molecularly Targeted Therapies examines opportunities for and challenges to the use of biomarker tests to select optimal therapy and offers recommendations to accelerate progress in this field. This report explores regulatory issues, reimbursement issues, and clinical practice issues related to the clinical development and use of biomarker tests for targeting therapies to patients. Properly validated, appropriately implemented biomarker tests hold the potential to enhance patient care and improve outcomes, and therefore addressing the challenges facing such tests is critical.
More Information
Rights Information
WW ex JP, CN, KR ; L
Marketing Information
http://www.nap.edu/21860
National Academies Press
The National Academies Press (NAP) publish the reports of the National Academies of Sciences, Engineering and Medicine. They published more than 200 books a year on a wide range of topics.
View all titlesBibliographic Information
- Publisher National Academies Press
- Publication Date September 2016
- Orginal LanguageEnglish
- ISBN/Identifier 9780309381345
- Publication Country or regionUnited States
- FormatPaperback
- Primary Price 62 USD
- Pages260
- ReadershipProfessional and scholarly
- Publish StatusPublished
- Dimensions9 x 6 inches
- Biblio Notes2016
Thank you for proceeding with this offer.
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
National Academies Press has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
Please wait while the payment is being prepared.
Do not close this window.
(c) Copyright 2024 - Frankfurt Rights. All Right Reserved